超眼看市｜创新药概念活跃，未名医药涨停

Group 1 - The A-share market saw all three major indices close higher, with the Shanghai Composite Index rising by 0.18% to 3461.15 points, the Shenzhen Component Index increasing by 1.17% to 10534.58 points, and the ChiNext Index up by 1.90% to 2164.09 points [1] - The trading volume in the Shanghai and Shenzhen markets was 1.3098 trillion yuan, a decrease of 67.2 billion yuan compared to the previous trading day [1] - Most industry sectors experienced gains, with notable increases in consumer electronics, biopharmaceuticals, electronic components, chemical pharmaceuticals, batteries, and traditional Chinese medicine [1] Group 2 - The Shandong sector saw nearly 60% of its stocks rise, with the innovative drug concept remaining active; Weiming Pharmaceutical hit the daily limit, while Baiyang Pharmaceutical and Chenxin Pharmaceutical rose over 7% [1] - Recent developments in Weiming Pharmaceutical's litigation and innovative drug research have attracted investor attention; the company announced on July 1 that a court dismissed a retrial lawsuit involving 30.48 million yuan, which will not negatively impact current or future profits [1] - Weiming Pharmaceutical's subsidiary, Shandong Yandu, is preparing to conduct Phase III clinical trials for an innovative ophthalmic biological drug [1] Group 3 - Dongxing Securities anticipates a trend of upward movement in the market, driven by heavyweight stocks, with a healthy market operation expected as it breaks through the 3400-point level [2] - The market is expected to see a healthy rotation of hotspots, primarily focusing on industry logic, with strong performance in sectors like military industry and solid-state batteries [2] - As the semi-annual reports approach, the market is likely to return to an industry logic trend, with a focus on performance-driven market styles, favoring high-dividend blue-chip companies [2]